George M. Warimwe

George M. Warimwe

Auto-generated profile, based on publicly available information

George M. Warimwe

Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Nairobi, Kenya

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Science
Verified
Journal Article
Open access
PDF file
SUSophie Uyoga
Sophie Uyoga
IAIfedayo M. O. Adetifa
Ifedayo M. O. Adetifa
HKHenry K. Karanja
Henry K. Karanja
JNJames Nyagwange
James Nyagwange
JTJames Tuju
James Tuju
GWGeorge M. Warimwe
George M. Warimwe
Pandemic progress in Kenya: By the end of July 2020, Kenya had reported only 341 deaths and ∼20,000 cases of COVID-19. This is in marked contrast to the tens of thousands of deaths reported in many higher-income countries. The true extent of COVID-19 in the community was unknown and likely to be higher than reports indicated. Uyoga et al. found an overall seroprevalence among blood donors of 4.3%, peaking in 35- to 44-year-old individuals (see the Perspective by Maeda and Nkengasong). The low mortality can be partly explained by the steep demographics in Kenya, where less than 4% of the population is 65 or older. These circumstances combine to result in Kenyan hospitals not currently being overwhelmed by patients with respiratory distress. However, the imposition of a strict lockdown in this country has shifted the disease burden to maternal and child deaths as a result of disruption to essential medical services. Science , this issue p. 79 ; see also p. 27

5 February 2016 in Scientific Reports
Verified
Journal Article
Open access
GWGeorge M. Warimwe
George M. Warimwe
JGJoseph Gesharisha
Joseph Gesharisha
BCB. Veronica Carr
B. Veronica Carr
SOSimeon Otieno
Simeon Otieno
KOKennedy Otingah
Kennedy Otingah
AHAdrian V. S. Hill
Adrian V. S. Hill
Rift Valley Fever virus (RVFV) causes recurrent outbreaks of acute life-threatening human and livestock illness in Africa and the Arabian Peninsula. No licensed vaccines are currently available for humans and those widely used in livestock have major safety concerns. A ‘One Health’ vaccine development approach, in which the same vaccine is co-developed for multiple susceptible species, is an attractive strategy for RVFV. Here, we utilized a replication-deficient chimpanzee adenovirus vaccine platform with an established human and livestock safety profile, ChAdOx1, to develop a vaccine for use against RVFV in both livestock and humans. We show that single-dose immunization with ChAdOx1-GnGc vaccine, encoding RVFV envelope glycoproteins, elicits high-titre RVFV-neutralizing antibody and provides solid protection against RVFV challenge in the most susceptible natural target species of the virus-sheep, goats and cattle. In addition we demonstrate induction of RVFV-neutralizing antibody by ChAdOx1-GnGc vaccination in dromedary camels, further illustrating the potency of replication-deficient chimpanzee adenovirus vaccine platforms. Thus, ChAdOx1-GnGc warrants evaluation in human clinical trials and could potentially address the unmet human and livestock vaccine needs.

23 August 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
SOStacey Orangi
Stacey Orangi
JPJessie Pinchoff
Jessie Pinchoff
DMDaniel Mwanga
Daniel Mwanga
TATimothy Abuya
Timothy Abuya
MHMainga Hamaluba
Mainga Hamaluba
EBEdwine Barasa
Edwine Barasa
The government of Kenya has launched a phased rollout of COVID-19 vaccination. A major barrier is vaccine hesitancy; the refusal or delay of accepting vaccination. This study evaluated the level and determinants of vaccine hesitancy in Kenya. We conducted a cross-sectional study administered through a phone-based survey in February 2021 in four counties of Kenya. Multilevel logistic regression was used to identify individual perceived risks and influences, context-specific factors and vaccine-specific issues associated with COVID-19 vaccine hesitancy. COVID-19 vaccine hesitancy in Kenya was high: 36.5%. Factors associated with vaccine hesitancy included: Rural regions, perceived difficulty in adhering to government regulations on COVID-19 prevention, no perceived COVID-19 infection risk, concerns regarding vaccine safety and effectiveness, and religious and cultural reasons. There is a need for the prioritization of interventions to address vaccine hesitancy and improve vaccine confidence as part of the vaccine roll-out plan. These messaging and/or interventions should be holistic to include the value of other public health measures, be focused and targeted to specific groups, raise awareness on the risks of COVID-19 and effectively communicate the benefits and risks of vaccines.

19 November 2021 in Science
Verified
Journal Article
Open access
SBSamuel P. C. Brand
Samuel P. C. Brand
JOJohn Ojal
John Ojal
RARabia Aziza
Rabia Aziza
VWVincent Omondi Were
Vincent Omondi Were
EOEmelda A. Okiro
Emelda A. Okiro
EBEdwine Barasa
Edwine Barasa
SARS-CoV-2: To have or to have not: In June 2021, official records in Kenya showed fewer than 4000 confirmed deaths and 180,000 confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These data tend to reflect the economically advantaged strata of society who can afford smartphones and have access to medical attention and tests. Brand et al . developed an epidemiological model to estimate the impact of the pandemic in Kenya, the population of which was split into two socioeconomic strata. The authors predicted that 75% of the Kenyan population (about 39 million people) had been exposed to the virus by June 2021. If a fourth wave of infection is observed in the future, it would likely be driven by a variant with enhanced transmissibility or natural immune escape. —CA

16 October 2017 in npj Vaccines
Verified
Journal Article
Open access
PDF file
VMVincent Munster
Vincent Munster
DWDaniel Wells
Daniel Wells
TLTeresa Lambe
Teresa Lambe
DWDaniel Wright
Daniel Wright
RFRobert J. Fischer
Robert J. Fischer
GWGeorge M. Warimwe
George M. Warimwe
Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel zoonotic virus that causes severe respiratory disease in humans with a case fatality rate close to 40%, but for which no vaccines are available. Here, we evaluated the utility of ChAdOx1, a promising replication-deficient simian adenovirus vaccine vector platform with an established safety profile in humans and dromedary camels, for MERS-CoV vaccine development. Using a transgenic lethal BALB/c MERS-CoV mouse model we showed that single dose intranasal or intramuscular immunisation with ChAdOx1 MERS, encoding full-length MERS-CoV Spike glycoprotein, is highly immunogenic and confers protection against lethal viral challenge. Immunogenicity and efficacy were comparable between immunisation routes. Together these data provide support for further evaluation of ChAdOx1 MERS vaccine in humans and dromedary camels, the animal reservoir of infection.

25 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
IAIfedayo M. O. Adetifa
Ifedayo M. O. Adetifa
SUSophie Uyoga
Sophie Uyoga
JGJohn N. Gitonga
John N. Gitonga
DMDaisy Mugo
Daisy Mugo
MOMark Otiende
Mark Otiende
GWGeorge M. Warimwe
George M. Warimwe
Observed SARS-CoV-2 infections and deaths are low in tropical Africa raising questions about the extent of transmission. We measured SARS-CoV-2 IgG by ELISA in 9,922 blood donors across Kenya and adjusted for sampling bias and test performance. By 1st September 2020, 577 COVID-19 deaths were observed nationwide and seroprevalence was 9.1% (95%CI 7.6-10.8%). Seroprevalence in Nairobi was 22.7% (18.0-27.7%). Although most people remained susceptible, SARS-CoV-2 had spread widely in Kenya with apparently low associated mortality.